Literature DB >> 17657251

Management of nonmelanoma skin cancer in 2007.

Julie A Neville1, Erin Welch, David J Leffell.   

Abstract

As the incidence of nonmelanoma skin cancer (NMSC) increases, so does the number of modalities used to treat this condition. Surgery is the most frequent approach used to treat NMSC, and clinicians usually perform Mohs micrographic surgery, conventional excision, electrodesiccation and curettage or cryosurgery. The 'gold standard' for treatment continues to be Mohs micrographic surgery, but owing to the time and expense involved with this procedure, it is indicated only in patients with aggressive tumors or those where disfigurement or functional impairment is a risk. Although radiation therapy is effective, its use is limited because of the side effects induced; radiation therapy can be used in certain patients who are not surgical candidates. Newer noninvasive options for NMSC include topical chemotherapeutics, biological-immune-response modifiers, retinoids, and photodynamic therapy, which can be used particularly in patients with superficial tumors. Treatments should be tailored to tumor type, location, size, and histological pattern, and although surgical methods remain the most frequently used, newer noninvasive treatments can be used in select tumors and may reduce morbidity.

Entities:  

Mesh:

Year:  2007        PMID: 17657251     DOI: 10.1038/ncponc0883

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  53 in total

1.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

2.  Transplantation: Does switching to a CNI-free regimen reduce cancer risk?

Authors:  Rebecca Ireland
Journal:  Nat Rev Nephrol       Date:  2011-08-30       Impact factor: 28.314

3.  IBD: UV protection and dermatological screening needed for IBD patients exposed to thiopurines.

Authors:  Natalie J Wood
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-09-02       Impact factor: 46.802

4.  Editorial: Local Immunotherapy: A Way to Convert Tumors From "Cold" to "Hot".

Authors:  Marijo Bilusic; James L Gulley
Journal:  J Natl Cancer Inst       Date:  2017-12-01       Impact factor: 13.506

5.  Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma.

Authors:  Mehdi Farshchian; Atte Kivisaari; Risto Ala-Aho; Pilvi Riihilä; Markku Kallajoki; Reidar Grénman; Juha Peltonen; Taina Pihlajaniemi; Ritva Heljasvaara; Veli-Matti Kähäri
Journal:  Am J Pathol       Date:  2011-07-01       Impact factor: 4.307

6.  Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention.

Authors:  Mohammad Athar; Levy Kopelovich
Journal:  Cancer Prev Res (Phila)       Date:  2011-07

7.  Three-dimensional imaging of normal skin and nonmelanoma skin cancer with cellular resolution using Gabor domain optical coherence microscopy.

Authors:  Kye-Sung Lee; Huimin Zhao; Sherrif F Ibrahim; Natthani Meemon; Laura Khoudeir; Jannick P Rolland
Journal:  J Biomed Opt       Date:  2012-12       Impact factor: 3.170

8.  Poly r(C) binding protein is post-transcriptionally repressed by MiR-490-3p to potentiate squamous cell carcinoma.

Authors:  Shan Xia; Zigang Zhao; Fang Xie; Jing He; Hengjin Li
Journal:  Tumour Biol       Date:  2016-09-15

9.  The initial experience of electronic brachytherapy for the treatment of non-melanoma skin cancer.

Authors:  Ajay Bhatnagar; Alphonse Loper
Journal:  Radiat Oncol       Date:  2010-09-28       Impact factor: 3.481

10.  Vismodegib (erivedge) for advanced Basal cell carcinoma.

Authors:  Chris Fellner
Journal:  P T       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.